Celltrion Pharm (Korea) Today
| 068760 Stock | KRW 62,400 900.00 1.46% |
Performance0 of 100
| Odds Of DistressLess than 9
|
Celltrion Pharm is trading at 62400.00 as of the 24th of December 2024, a 1.46 percent increase since the beginning of the trading day. The stock's open price was 61500.0. Celltrion Pharm has less than a 9 % chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days.Celltrion Pharm has reported 1 for 1 split on 27th of December 2024. The performance scores are derived for the period starting the 24th of November 2024 and ending today, the 24th of December 2024. Click here to learn more.
Celltrion Pharm, Inc., a pharmaceutical company, develops and sells biosimilars and over-the-counter drugs in South Korea. Celltrion Pharm Inc. was founded in 1976 and is based in Cheongju, South Korea. Celltrionph is traded on Korean Securities Dealers Automated Quotations in South Korea.. The company has 34.05 M outstanding shares. More on Celltrion Pharm
Moving together with Celltrion Stock
Moving against Celltrion Stock
Celltrion Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Celltrion Pharm's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Celltrion Pharm or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Jeong Seo |
| Business Concentration | Health Care, Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) |
Celltrion Pharm (068760) is traded on KOSDAQ in Korea and employs 29 people. The company currently falls under 'Mega-Cap' category with a current market capitalization of 2.1 T. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Celltrion Pharm's market, we take the total number of its shares issued and multiply it by Celltrion Pharm's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Celltrion Pharm operates under Pharmaceuticals sector and is part of Health Care industry. The entity has 34.05 M outstanding shares.
Celltrion Pharm has accumulated about 80.19 B in cash with 93.15 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 815.33.
Check Celltrion Pharm Probability Of Bankruptcy
Ownership AllocationCelltrion Pharm holds a total of 34.05 Million outstanding shares. Celltrion Pharm retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Celltrion Ownership Details
Celltrion Pharm Risk Profiles
Although Celltrion Pharm's alpha and beta are two of the key measurements used to evaluate Celltrion Pharm's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 2.11 | |||
| Standard Deviation | 2.96 | |||
| Variance | 8.73 | |||
| Risk Adjusted Performance | (0.02) |
Celltrion Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Celltrion Pharm without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Optimization Now
Portfolio OptimizationCompute new portfolio that will generate highest expected return given your specified tolerance for risk |
| All Next | Launch Module |
Celltrion Pharm Corporate Directors
| Haeng Kim | Non-Executive Independent Director | Profile | |
| Gyeong Kim | Non-Executive Independent Director | Profile | |
| Seung Choi | Managing Director | Profile | |
| Jin Wang | Assistant Managing Director | Profile |
Other Information on Investing in Celltrion Stock
Celltrion Pharm financial ratios help investors to determine whether Celltrion Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Celltrion with respect to the benefits of owning Celltrion Pharm security.